ShammasNWLemkeJHDippelEJ. In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant. J Invasive Cardiol. 2003;15:242–246.
2.
ShammasNW. Complications in peripheral vascular interventions: Emerging role of direct thrombin inhibitors. J Vasc Interv Radiol. 2005;16(2 Pt 1):165–171.
3.
SmithFBRumleyALeeAJ. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol. 1998;100:758–763.
4.
McDermottMMGreenDGreenlandP. Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol. 2003;92:194–199.
5.
RoblessPAOkonkoDLintottP. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2003;25:16–22.
6.
AllieDEHallPShammasNW. The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): In-hospital and 30-day results. J Invasive Cardiol. 2004;16:651–656.
7.
ShammasNWShammasGAJerinM. In-hospital safety and effectiveness of bivalirudin in percutaneous peripheral interventions: Data from a real-world registry. J Endovasc Ther. 2010;17:31–36.
8.
BurgessJKChongBH. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls. Eur J Haematol. 1997;58:279–285.
9.
XiaoZThérouxP.Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251–256.
10.
MahaffeyKWLewisBEWildermannNM. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: Main results. J Invasive Cardiol. 2003;15:611–616.
11.
ShammasNW. Bivalirudin: Pharmacology and clinical applications. Cardiovasc Drug Rev. 2005;23:345–360.
12.
LincoffAMKleimanNSKereiakesDJ. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA. 2004;292:696–703.
13.
BittlJAChaitmanBRFeitF. Bivalirudin versus heparin during coronary angioplasty for unstable or post infarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J.2001;142:952–959.
14.
LincoffAMBittlJAHarringtonRA. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa during percutaneous coronary intervention; the REPLACE-2 randomized trial. JAMA. 2003;289:853–863.
15.
ShahPBAhmedWHGanzP. Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions. J Am Coll Cardiol. 1997;30:1264–1269.
16.
Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: Principal results of a meta-analysis based on individual patients' data. Lancet. 2002;359:294–302.
17.
StoneGWMcLaurinBTCoxDA. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203–2216.
